发明名称 |
USE OF MLKL IN CANCER THERAPY |
摘要 |
The present invention pertains to the field of therapeutic and diagnostic compositions. Specifically, it relates to a polynucleotide comprising a nucleic acid sequence encoding a MLKL polypeptide or variants thereof for use as medicament. The present invention relates further to a nucleic acid which specifically binds to a polynucleotide encoding a MLKL polypeptide for use as a medicament, whereby the nucleic acid upon specific binding prevents the generation of a biologically active polypeptide encoded by the said polynucleotide. Additionally, the present invention relates to an antibody or an RNA- aptamer which specifically recognizes a polypeptide encoded by a polynucleotide as specified above for use as a medicament. The present invention also relates to the use of a polynucleotide of the present invention, a nucleic acid of the present invention, or an antibody of the present invention for the manufacture of a medicament for the treatment of cancer. The present invention relates to methods for diagnosing cancer in a subject, methods for assessing whether a subject suffering from cancer will benefit from a MLKL based anti-cancer treatment, methods for identifying MLKL modulators, and a method for the manufacture of medicament comprising the steps of the aforementioned methods and a further step of formulating the modulator as a medicament. |
申请公布号 |
WO2010122135(A2) |
申请公布日期 |
2010.10.28 |
申请号 |
WO2010EP55418 |
申请日期 |
2010.04.23 |
申请人 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM;MOLLENHAUER, JAN;HUDLER, MELANIE;BLAICH, STEPHANIE;WITTIG, RAINER |
发明人 |
MOLLENHAUER, JAN;HUDLER, MELANIE;BLAICH, STEPHANIE;WITTIG, RAINER |
分类号 |
C12N9/12;A61K38/45 |
主分类号 |
C12N9/12 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|